GlassScriptPhysician profile
Elizabeth C Lee
NPI 1790051951
$3,634.84
in general payments reported to CMS, 2019-2025
25 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $128 · 2021: $736 · 2022: $952 · 2023: $738 · 2024: $411 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,250.98 | 2020-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $359.05 | 2020-2025 | |
| Boston Scientific Corporation | $318.12 | 2019-2022 | |
| Cvrx, INC. | $311.27 | 2023-2025 | Barostim Neo System |
| Abiomed | $272.61 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $232.09 | 2020-2025 | Wainua |
| Impulse Dynamics (USA) INC. | $149.97 | 2021-2024 | Optimizer |
| Alnylam Pharmaceuticals INC. | $119.03 | 2021-2025 | Onpattro |
| Kestra Medical Technology Services, INC. | $87.76 | 2022-2024 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.12 | 2020-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $68.04 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $55.55 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $55.24 | 2022-2023 | Verquvo |
| Daiichi Sankyo INC. | $51.50 | 2023-2025 | Injectafer |
| Pfizer INC. | $42.83 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $30.39 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Scpharmaceuticals INC. | $22.58 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.25 | 2025 | |
| Glaxosmithkline, LLC. | $21.00 | 2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $20.30 | 2023 | Ozempic |
| Bridgebio Pharma, INC. | $19.97 | 2025 | Attruby |
| Astellas Pharma US INC | $18.65 | 2020 | |
| Edwards Lifesciences Corporation | $14.09 | 2022 | |
| Amgen INC. | $11.45 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.